Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ag85B-ESAT-6 + CAF01
- Development stage
- Unknown
- Lead developer
- Statens Serum Institut
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ag85B-ESAT-6 + CAF01 is a subunit tuberculosis (TB) vaccine candidate composed of a recombinant fusion protein antigen (Ag85B fused to ESAT-6 from Mycobacterium tuberculosis) formulated with the liposomal adjuvant system CAF01. The combination is designed to induce strong and long-lasting cellular immune responses, particularly Th1-type immunity characterized by IFN-gamma production and antigen-specific CD4+ T-cell activation. The adjuvant CAF01 enhances the immunogenicity of the protein antigen by promoting robust T-cell responses necessary for protection against TB. Clinical studies have shown that this formulation is safe and well-tolerated in humans, eliciting persistent memory T-cell responses without significant adverse effects. Developed primarily for prevention of tuberculosis infection or disease progression, it has been evaluated in both preclinical models and early-phase human clinical trials[2][3][4].
- Other names
- H1/CAF01TB subunit vaccine (Ag85B-ESAT-6 + CAF01)
02
Targets
MHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on Ag85B-ESAT-6 + CAF01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ag85B-ESAT-6 + CAF01.